The Pediatric Cardiomyopathy Registry: 1995-2007

James D. Wilkinson, Lynn A. Sleeper, Jorge A. Alvarez, Natalya Bublik, Steven E Lipshultz

Research output: Contribution to journalArticle

32 Citations (Scopus)

Abstract

Cardiomyopathy is a serious disorder of the heart muscle and, although rare, it is potentially devastating in children. Funded by the National Heart Lung and Blood Institute since 1994, the Pediatric Cardiomyopathy Registry (PCMR) was designed to describe the epidemiology and clinical course of selected CMs in patients 18 years old or younger and to promote the development of etiology-specific prevention and treatment strategies. Currently, data from more than 3000 children with cardiomyopathy have been entered in the PCMR database with annual follow-up continuing until death, heart transplant, or loss-to-follow up. Using PCMR data, the incidence of cardiomyopathy in two large regions of the United States is estimated to be 1.13 cases per 100,000 children. Only 1/3 of children had a known etiology at the time of cardiomyopathy diagnosis. Diagnosis was associated with certain patient characteristics, family history, echocardiographic findings, laboratory testing, and biopsy. Greater incidence was found in boys and infants (< 1 yr) for both dilated and hypertrophic cardiomyopathy (DCM, HCM) and black race for only DCM. In DCM, prognosis is worse in older children (> 1 yr), heart failure (HF) at diagnosis or idiopathic etiology. For HCM, worse prognosis is associated with inborn errors of metabolism or combination of HCM and another cardiomyopathy functional type. The best outcomes were observed in children presenting at age > 1 yr with idiopathic HCM. PCMR data have enabled analysis of patients with cardiomyopathy and muscular dystrophy, as well as Noonan Syndrome. Currently, collaborations with the Pediatric Heart Transplant Study group and a newly established Pediatric Cardiomyopathy Biologic Specimen Repository at Texas Children's Hospital will continue to yield important results. The PCMR is the largest and most complete multi-center prospective data resource regarding the etiology, clinical course and outcomes for children with cardiomyopathy.

Original languageEnglish
Pages (from-to)31-36
Number of pages6
JournalProgress in Pediatric Cardiology
Volume25
Issue number1
DOIs
StatePublished - Apr 1 2008

Fingerprint

Cardiomyopathies
Registries
Pediatrics
Noonan Syndrome
National Heart, Lung, and Blood Institute (U.S.)
Transplants
Inborn Errors Metabolism
Muscular Dystrophies
Incidence
Myocardium
Epidemiology
Heart Failure
Databases
Biopsy

Keywords

  • Cardiomyopathy
  • Heart failure
  • Muscular dystrophy
  • Pediatric Cardiomyopathy Registry
  • Pediatric Cardiomyopathy Registry.

ASJC Scopus subject areas

  • Cardiology and Cardiovascular Medicine

Cite this

Wilkinson, J. D., Sleeper, L. A., Alvarez, J. A., Bublik, N., & Lipshultz, S. E. (2008). The Pediatric Cardiomyopathy Registry: 1995-2007. Progress in Pediatric Cardiology, 25(1), 31-36. https://doi.org/10.1016/j.ppedcard.2007.11.006

The Pediatric Cardiomyopathy Registry : 1995-2007. / Wilkinson, James D.; Sleeper, Lynn A.; Alvarez, Jorge A.; Bublik, Natalya; Lipshultz, Steven E.

In: Progress in Pediatric Cardiology, Vol. 25, No. 1, 01.04.2008, p. 31-36.

Research output: Contribution to journalArticle

Wilkinson, JD, Sleeper, LA, Alvarez, JA, Bublik, N & Lipshultz, SE 2008, 'The Pediatric Cardiomyopathy Registry: 1995-2007', Progress in Pediatric Cardiology, vol. 25, no. 1, pp. 31-36. https://doi.org/10.1016/j.ppedcard.2007.11.006
Wilkinson JD, Sleeper LA, Alvarez JA, Bublik N, Lipshultz SE. The Pediatric Cardiomyopathy Registry: 1995-2007. Progress in Pediatric Cardiology. 2008 Apr 1;25(1):31-36. https://doi.org/10.1016/j.ppedcard.2007.11.006
Wilkinson, James D. ; Sleeper, Lynn A. ; Alvarez, Jorge A. ; Bublik, Natalya ; Lipshultz, Steven E. / The Pediatric Cardiomyopathy Registry : 1995-2007. In: Progress in Pediatric Cardiology. 2008 ; Vol. 25, No. 1. pp. 31-36.
@article{d41ae93d07db47d88d71074e4442e0f7,
title = "The Pediatric Cardiomyopathy Registry: 1995-2007",
abstract = "Cardiomyopathy is a serious disorder of the heart muscle and, although rare, it is potentially devastating in children. Funded by the National Heart Lung and Blood Institute since 1994, the Pediatric Cardiomyopathy Registry (PCMR) was designed to describe the epidemiology and clinical course of selected CMs in patients 18 years old or younger and to promote the development of etiology-specific prevention and treatment strategies. Currently, data from more than 3000 children with cardiomyopathy have been entered in the PCMR database with annual follow-up continuing until death, heart transplant, or loss-to-follow up. Using PCMR data, the incidence of cardiomyopathy in two large regions of the United States is estimated to be 1.13 cases per 100,000 children. Only 1/3 of children had a known etiology at the time of cardiomyopathy diagnosis. Diagnosis was associated with certain patient characteristics, family history, echocardiographic findings, laboratory testing, and biopsy. Greater incidence was found in boys and infants (< 1 yr) for both dilated and hypertrophic cardiomyopathy (DCM, HCM) and black race for only DCM. In DCM, prognosis is worse in older children (> 1 yr), heart failure (HF) at diagnosis or idiopathic etiology. For HCM, worse prognosis is associated with inborn errors of metabolism or combination of HCM and another cardiomyopathy functional type. The best outcomes were observed in children presenting at age > 1 yr with idiopathic HCM. PCMR data have enabled analysis of patients with cardiomyopathy and muscular dystrophy, as well as Noonan Syndrome. Currently, collaborations with the Pediatric Heart Transplant Study group and a newly established Pediatric Cardiomyopathy Biologic Specimen Repository at Texas Children's Hospital will continue to yield important results. The PCMR is the largest and most complete multi-center prospective data resource regarding the etiology, clinical course and outcomes for children with cardiomyopathy.",
keywords = "Cardiomyopathy, Heart failure, Muscular dystrophy, Pediatric Cardiomyopathy Registry, Pediatric Cardiomyopathy Registry.",
author = "Wilkinson, {James D.} and Sleeper, {Lynn A.} and Alvarez, {Jorge A.} and Natalya Bublik and Lipshultz, {Steven E}",
year = "2008",
month = "4",
day = "1",
doi = "10.1016/j.ppedcard.2007.11.006",
language = "English",
volume = "25",
pages = "31--36",
journal = "Progress in Pediatric Cardiology",
issn = "1058-9813",
publisher = "Elsevier Ireland Ltd",
number = "1",

}

TY - JOUR

T1 - The Pediatric Cardiomyopathy Registry

T2 - 1995-2007

AU - Wilkinson, James D.

AU - Sleeper, Lynn A.

AU - Alvarez, Jorge A.

AU - Bublik, Natalya

AU - Lipshultz, Steven E

PY - 2008/4/1

Y1 - 2008/4/1

N2 - Cardiomyopathy is a serious disorder of the heart muscle and, although rare, it is potentially devastating in children. Funded by the National Heart Lung and Blood Institute since 1994, the Pediatric Cardiomyopathy Registry (PCMR) was designed to describe the epidemiology and clinical course of selected CMs in patients 18 years old or younger and to promote the development of etiology-specific prevention and treatment strategies. Currently, data from more than 3000 children with cardiomyopathy have been entered in the PCMR database with annual follow-up continuing until death, heart transplant, or loss-to-follow up. Using PCMR data, the incidence of cardiomyopathy in two large regions of the United States is estimated to be 1.13 cases per 100,000 children. Only 1/3 of children had a known etiology at the time of cardiomyopathy diagnosis. Diagnosis was associated with certain patient characteristics, family history, echocardiographic findings, laboratory testing, and biopsy. Greater incidence was found in boys and infants (< 1 yr) for both dilated and hypertrophic cardiomyopathy (DCM, HCM) and black race for only DCM. In DCM, prognosis is worse in older children (> 1 yr), heart failure (HF) at diagnosis or idiopathic etiology. For HCM, worse prognosis is associated with inborn errors of metabolism or combination of HCM and another cardiomyopathy functional type. The best outcomes were observed in children presenting at age > 1 yr with idiopathic HCM. PCMR data have enabled analysis of patients with cardiomyopathy and muscular dystrophy, as well as Noonan Syndrome. Currently, collaborations with the Pediatric Heart Transplant Study group and a newly established Pediatric Cardiomyopathy Biologic Specimen Repository at Texas Children's Hospital will continue to yield important results. The PCMR is the largest and most complete multi-center prospective data resource regarding the etiology, clinical course and outcomes for children with cardiomyopathy.

AB - Cardiomyopathy is a serious disorder of the heart muscle and, although rare, it is potentially devastating in children. Funded by the National Heart Lung and Blood Institute since 1994, the Pediatric Cardiomyopathy Registry (PCMR) was designed to describe the epidemiology and clinical course of selected CMs in patients 18 years old or younger and to promote the development of etiology-specific prevention and treatment strategies. Currently, data from more than 3000 children with cardiomyopathy have been entered in the PCMR database with annual follow-up continuing until death, heart transplant, or loss-to-follow up. Using PCMR data, the incidence of cardiomyopathy in two large regions of the United States is estimated to be 1.13 cases per 100,000 children. Only 1/3 of children had a known etiology at the time of cardiomyopathy diagnosis. Diagnosis was associated with certain patient characteristics, family history, echocardiographic findings, laboratory testing, and biopsy. Greater incidence was found in boys and infants (< 1 yr) for both dilated and hypertrophic cardiomyopathy (DCM, HCM) and black race for only DCM. In DCM, prognosis is worse in older children (> 1 yr), heart failure (HF) at diagnosis or idiopathic etiology. For HCM, worse prognosis is associated with inborn errors of metabolism or combination of HCM and another cardiomyopathy functional type. The best outcomes were observed in children presenting at age > 1 yr with idiopathic HCM. PCMR data have enabled analysis of patients with cardiomyopathy and muscular dystrophy, as well as Noonan Syndrome. Currently, collaborations with the Pediatric Heart Transplant Study group and a newly established Pediatric Cardiomyopathy Biologic Specimen Repository at Texas Children's Hospital will continue to yield important results. The PCMR is the largest and most complete multi-center prospective data resource regarding the etiology, clinical course and outcomes for children with cardiomyopathy.

KW - Cardiomyopathy

KW - Heart failure

KW - Muscular dystrophy

KW - Pediatric Cardiomyopathy Registry

KW - Pediatric Cardiomyopathy Registry.

UR - http://www.scopus.com/inward/record.url?scp=40949159750&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=40949159750&partnerID=8YFLogxK

U2 - 10.1016/j.ppedcard.2007.11.006

DO - 10.1016/j.ppedcard.2007.11.006

M3 - Article

AN - SCOPUS:40949159750

VL - 25

SP - 31

EP - 36

JO - Progress in Pediatric Cardiology

JF - Progress in Pediatric Cardiology

SN - 1058-9813

IS - 1

ER -